{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:51:55Z","timestamp":1761947515724},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,11,7]],"date-time":"2008-11-07T00:00:00Z","timestamp":1226016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s10549-008-0236-6","type":"journal-article","created":{"date-parts":[[2008,11,6]],"date-time":"2008-11-06T15:08:15Z","timestamp":1225984095000},"page":"307-313","source":"Crossref","is-referenced-by-count":12,"title":["Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease"],"prefix":"10.1007","volume":"118","author":[{"given":"E. R.","family":"van Beek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. W. G. M.","family":"Lowik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"van Wijngaarden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. H.","family":"Ebetino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,11,7]]},"reference":[{"key":"236_CR1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176. doi: 10.1053\/ctrv.2000.0210","journal-title":"Cancer Treat Rev"},{"key":"236_CR2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655\u20131664. doi: 10.1056\/NEJMra030831","journal-title":"N Engl J Med"},{"key":"236_CR3","doi-asserted-by":"crossref","unstructured":"K\u00e4k\u00f6nen SM, Mundy GR (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97(3)(suppl):834\u2013839. doi: 10.1002\/cncr.11132","DOI":"10.1002\/cncr.11132"},{"key":"236_CR4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","volume":"19","author":"M Aapro","year":"2008","unstructured":"Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420\u2013432. doi: 10.1093\/annonc\/mdm442","journal-title":"Ann Oncol"},{"key":"236_CR5","doi-asserted-by":"crossref","unstructured":"Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97(3)(suppl):840\u2013847. doi: 10.1002\/cncr.11128","DOI":"10.1002\/cncr.11128"},{"key":"236_CR6","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","volume":"65","author":"P Clezardin","year":"2005","unstructured":"Clezardin P, Ebetino FH, Fournier PGJ (2005) Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65:4971\u20134974. doi: 10.1158\/0008-5472.CAN-05-0264","journal-title":"Cancer Res"},{"key":"236_CR7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2007.07.007","volume":"257","author":"V Stresing","year":"2007","unstructured":"Stresing V, Daubin\u00e9 F, Benzaid I, M\u00f6nkk\u00f6nen H, Cl\u00e9zardin P (2007) Bisphosphonates in cancer therapy. Cancer Lett 257:16\u201335. doi: 10.1016\/j.canlet.2007.07.007","journal-title":"Cancer Lett"},{"key":"236_CR8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","volume":"98","author":"G Pluijm van der","year":"1996","unstructured":"van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, L\u00f6wik C, Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698\u2013705. doi: 10.1172\/JCI118841","journal-title":"J Clin Invest"},{"key":"236_CR9","first-page":"3551","volume":"55","author":"A Sasaki","year":"1995","unstructured":"Sasaki A, Boyce BF, Story B et al (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551\u20133557","journal-title":"Cancer Res"},{"key":"236_CR10","first-page":"5452","volume":"53","author":"PJ Kostenuik","year":"1993","unstructured":"Kostenuik PJ, Orr FW, Suyama K et al (1993) Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res 53:5452\u20135457","journal-title":"Cancer Res"},{"key":"236_CR11","first-page":"4418","volume":"61","author":"T Hiraga","year":"2001","unstructured":"Hiraga T, Williams PJ, Mundy GR et al (2001) The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61:4418\u20134424","journal-title":"Cancer Res"},{"key":"236_CR12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/1097-0142(19930701)72:1<91::AID-CNCR2820720118>3.0.CO;2-2","volume":"72","author":"B Krempien","year":"1993","unstructured":"Krempien B, Manegold C (1993) Prophylactic treatment of skeletal metastases, tumor induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP. Cancer 72:91\u201398. doi:10.1002\/1097-0142(19930701)72:1<91::AID-CNCR2820720118>3.0.CO;2-2","journal-title":"Cancer"},{"key":"236_CR13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000226528","volume":"45","author":"B Krempien","year":"1988","unstructured":"Krempien B, Wingen F, Eichmann T et al (1988) Protective effect of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1,1 bisphosphonic acid on the development of tumor osteopathies in rat: experimental studies with the Walker Carcinosarcoma 256. Oncology 45:41\u201346","journal-title":"Oncology"},{"key":"236_CR14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650090211","volume":"9","author":"DG Hall","year":"1994","unstructured":"Hall DG, Stoica G (1994) Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res 9:221\u2013230","journal-title":"J Bone Miner Res"},{"key":"236_CR15","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1158\/0008-5472.CAN-04-4188","volume":"65","author":"G Pluijm van der","year":"2005","unstructured":"van der Pluijm G, Que I, Sijmons B et al (2005) Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 65:7682\u20137690. doi: 10.1158\/0008-5472.CAN-05-2468","journal-title":"Cancer Res"},{"key":"236_CR16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","volume":"99","author":"F Daubine","year":"2007","unstructured":"Daubine F, Le Gall C, Gasser J, Green J, Clezardin P (2007) Antitumour effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99:322\u2013330. doi: 10.1093\/jnci\/djk054","journal-title":"J Natl Cancer Inst"},{"key":"236_CR17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1023\/A:1022621622063","volume":"20","author":"H Zhang","year":"2003","unstructured":"Zhang H, Yano S, Miki T et al (2003) A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small cell lung cancer cells in NK-cell depleted SCID mice. Clin Exp Metastasis 20:153\u2013159. doi: 10.1023\/A:1022621622063","journal-title":"Clin Exp Metastasis"},{"key":"236_CR18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","volume":"37","author":"D Heymann","year":"2005","unstructured":"Heymann D, Ory B, Blanchard F et al (2005) Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37:74\u201386. doi: 10.1016\/j.bone.2005.02.020","journal-title":"Bone"},{"key":"236_CR19","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1158\/0008-5472.CAN-04-3601","volume":"65","author":"SJ Kim","year":"2005","unstructured":"Kim SJ, Uehara H, Yazici S et al (2005) Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 65:3707\u20133715. doi: 10.1158\/0008-5472.CAN-04-3601","journal-title":"Cancer Res"},{"key":"236_CR20","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1158\/1078-0432.CCR-05-1010","volume":"11","author":"K Inoue","year":"2005","unstructured":"Inoue K, Karashima T, Fukata S et al (2005) Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma. Clin Cancer Res 11:6669\u20136677. doi: 10.1158\/1078-0432.CCR-05-1010","journal-title":"Clin Cancer Res"},{"key":"236_CR21","first-page":"5380","volume":"9","author":"S Yano","year":"2003","unstructured":"Yano S, Zhang H, Hanibuchi M et al (2003) Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice. Clin Cancer Res 9:5380\u20135385","journal-title":"Clin Cancer Res"},{"issue":"3","key":"236_CR22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1019905111666","volume":"75","author":"T Michigami","year":"2002","unstructured":"Michigami T, Hiraga T, Williams PJ et al (2002) The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 75(3):249\u2013258. doi: 10.1023\/A:1019905111666","journal-title":"Breast Cancer Res Treat"},{"key":"236_CR23","first-page":"116","volume":"16","author":"ME Stearns","year":"1996","unstructured":"Stearns ME, Wang M (1996) Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 16:116\u2013131","journal-title":"Invasion Metastasis"},{"key":"236_CR24","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0002-9440(10)64934-6","volume":"160","author":"A Wetterwald","year":"2002","unstructured":"Wetterwald A, van der Pluijm G, Que I et al (2002) Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol 160:1143\u20131153","journal-title":"Am J Pathol"},{"key":"236_CR25","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0002-9440(10)61773-7","volume":"159","author":"G Pluijm van der","year":"2001","unstructured":"van der Pluijm G, Sijmons B, Vloedgraven H et al (2001) Urokinasereceptor\/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol 159:971\u2013982","journal-title":"Am J Pathol"},{"key":"236_CR26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.1800457","volume":"180","author":"BC Eerden van der","year":"2004","unstructured":"van der Eerden BC, L\u00f6wik CW, Wit JM, Karperien M (2004) Expression of estrogen receptors and enzymes involved in sex steroid metabolism in the rat tibia during sexual maturation. J Endocrinol 180:457\u2013467. doi: 10.1677\/joe.0.1800457","journal-title":"J Endocrinol"},{"key":"236_CR27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1359\/jbmr.1998.13.2.253","volume":"13","author":"RJ Brown","year":"1998","unstructured":"Brown RJ, van Beek E, Watts DJ, L\u00f6wik CW, Papapoulos SE (1998) Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum. J Bone Miner Res 13:253\u2013258. doi: 10.1359\/jbmr.1998.13.2.253","journal-title":"J Bone Miner Res"},{"key":"236_CR28","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","volume":"89","author":"JE Brown","year":"2003","unstructured":"Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89:2031\u20132037. doi: 10.1038\/sj.bjc.6601437","journal-title":"Br J Cancer"},{"key":"236_CR29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumours. J Natl Cancer Inst 97:59\u201369","journal-title":"J Natl Cancer Inst"},{"key":"236_CR30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10555-006-9033-z","volume":"25","author":"J Liao","year":"2006","unstructured":"Liao J, McCauley LK (2006) Skeletal metastasis: established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 25:559\u2013571","journal-title":"Cancer Metastasis Rev"},{"key":"236_CR31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10555-006-9023-1","volume":"25","author":"VA Siclari","year":"2006","unstructured":"Siclari VA, Guise TA, Chirgwin JM (2006) Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 25:621\u2013623. doi: 10.1007\/s10555-006-9023-1","journal-title":"Cancer Metastasis Rev"},{"key":"236_CR32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","volume":"44","author":"SCLM Cremers","year":"2005","unstructured":"Cremers SCLM, Pillai G, Papapoulos SE (2005) Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimization of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551\u2013570. doi: 10.2165\/00003088-200544060-00001","journal-title":"Clin Pharmacokinet"},{"key":"236_CR33","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1359\/JBMR.050522","volume":"20","author":"SCLM Cremers","year":"2005","unstructured":"Cremers SCLM, Papapoulos SE, Gelderblom H et al (2005) Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res 20:1543\u20131547. doi: 10.1359\/JBMR.050522","journal-title":"J Bone Miner Res"},{"key":"236_CR34","doi-asserted-by":"crossref","first-page":"8945","DOI":"10.1158\/0008-5472.CAN-08-2195","volume":"68","author":"PGJ Fournier","year":"2008","unstructured":"Fournier PGJ, Daubin\u00e9 F, Lundy MW, Rogers MJ, Ebetino FH, Cl\u00e9zardin P (2008) Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Cancer Res 68:8945\u20138953","journal-title":"Cancer Res"},{"key":"236_CR35","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","volume":"84","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI (2001) The bisphosphonate zoledronic acid induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84:1126\u20131134. doi: 10.1054\/bjoc.2001.1727","journal-title":"Br J Cancer"},{"key":"236_CR36","first-page":"664a","volume":"19","author":"SP Jagdev","year":"2000","unstructured":"Jagdev SP, Croucher PI, Coleman RE (2000) Zoledronic acid induces apoptosis of breast cancer cells in vitro: evidence for additive and synergistic effects with taxol and tamoxifene. Proc Am Soc Clin Oncol 19:664a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"236_CR37","doi-asserted-by":"crossref","unstructured":"Ottewell PD, Deux B, M\u00f6nkk\u00f6nen H, Cross S, Coleman RE, Clezardin P, Holen I (2008) Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 15; 14(14):4658\u20134666","DOI":"10.1158\/1078-0432.CCR-07-1545"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-008-0236-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0236-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:29:03Z","timestamp":1559233743000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-008-0236-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,7]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["236"],"URL":"https:\/\/doi.org\/10.1007\/s10549-008-0236-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,7]]}}}